Glaucoma is the second leading cause of blindness in the world, affecting more than 60 million people globally. In order to reduce the progression of the disease, both medical and surgical treatments are used. Frequent side effects of both treatments include a range of modifications of the ocular surface grouped as the Ocular Surface Disease (OSD), which include Dry Eye Disease (DED). DED and other OSD negatively impact on the success of anti-glaucoma treatments and reduce the adherence to medical therapies. Tear film osmolarity (TFO) is a relatively novel test which has become a hallmark of DED. The aim of this paper was to review the association between OSD, DED and glaucoma in view of published TFO data, and to discuss future fields of research and treatments on the topic of glaucoma iatrogenic damage.

Tear film osmolarity, ocular surface disease and glaucoma: A review / P. Fogagnolo, G. Torregrossa, L. Tranchina, A. Ferreras, S. De Cilla, A. Labbe, M. Figus, L. Ottobelli, L. Rossetti. - In: CURRENT MEDICINAL CHEMISTRY. - ISSN 0929-8673. - 26:22(2019 Jun), pp. 4241-4252. [10.2174/0929867326666190725160621]

Tear film osmolarity, ocular surface disease and glaucoma: A review

P. Fogagnolo;G. Torregrossa;M. Figus;L. Ottobelli;L. Rossetti
2019

Abstract

Glaucoma is the second leading cause of blindness in the world, affecting more than 60 million people globally. In order to reduce the progression of the disease, both medical and surgical treatments are used. Frequent side effects of both treatments include a range of modifications of the ocular surface grouped as the Ocular Surface Disease (OSD), which include Dry Eye Disease (DED). DED and other OSD negatively impact on the success of anti-glaucoma treatments and reduce the adherence to medical therapies. Tear film osmolarity (TFO) is a relatively novel test which has become a hallmark of DED. The aim of this paper was to review the association between OSD, DED and glaucoma in view of published TFO data, and to discuss future fields of research and treatments on the topic of glaucoma iatrogenic damage.
Benzalkonium chloride; Blindness; Dry eye disease; Glaucoma; Ocular surface disease; Tear film osmolarity; Animals; Antihypertensive Agents; Corneal Diseases; Glaucoma; Humans; Osmolar Concentration; Preservatives, Pharmaceutical; Surface Properties; Tears
Settore MED/30 - Malattie Apparato Visivo
giu-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
0011C.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 1.09 MB
Formato Adobe PDF
1.09 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/723720
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 8
social impact